Study summary · research use only
Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This meta-analysis of randomized controlled trials in non-diabetic human adults with obesity pooled five RCTs of mazdutide, a dual GLP-1 and glucagon receptor agonist, searched via Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov. The abstract reports that mazdutide was associated with reductions in percentage body weight (mean difference -12.42%), absolute body weight (-9.76 kg), and waist circumference (-7.98 cm), along with decreases in systolic blood pressure (-7.68 mmHg), total cholesterol (-0.57 mmol/L) and LDL (-0.37 mmol/L). Adverse events were slightly increased (RR = 1.12), and a dose-response meta-regression showed a significant effect (β = -0.99, p = 0.0187). The authors note findings are limited by the small number of included RCTs.
Abstract
Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity. A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity. Meta-analysis was performed using RevMan 5.4 with random-effect models. Five RCTs were included. Mazdutide significantly reduced percentage body weight (MD = -12.42%, 95% CI: -16.15% to -8.68%), absolute body weight (MD = -9.76 kg, 95% CI: -13.15 to -6.37 kg) and waist circumference (MD = -7.98 cm, 95% CI: -10.24 to -5.72 cm). Systolic blood pressure (MD = -7.68 mmHg), total cholesterol (MD = -0.57 mmol/L) and LDL (MD = -0.37 mmol/L) also decreased. Adverse events were slightly increased (RR = 1.12). Dose-wise meta-regression showed significant effects (β = -0.99, 95% CI: -1.81 to -0.16; p = 0.0187). Mazdutide effectively reduces weight, waist circumference and blood pressure but may cause mild to moderate adverse events. Findings are limited by the small number of RCTs.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.